Shifting the Perspective of Therapy Options in Early-Stage NSCLC

Liza Villaruz, MD


January 30, 2023

Liza Villaruz, MD, discusses the paradigm shift that has occurred in the testing and treatment of patients with early-stage non–small cell lung cancer (NSCLC). Dr Villaruz no longer looks at early-stage NSCLC as a single-disease entity but as a complex disease stage with subsets.

With this perspective shift over the last couple of decades, Dr Villaruz has witnessed the use of genomic testing to guide therapy options that target individual subtypes in early-stage NSCLC.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.